Neurodegenerative Disorders Research

Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005
ABN: 86 139 590 319
Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au
Web: www.ndr.org.au

OLEX Interventional Study: Alzheimer's Disease and Frontotemporal Dementia

Study

An open-label, extension study of the effects of leuco methylthioninium bis (hydromethanesulfonate) – LMTM – in subjects with Alzheimer's disease or behavioral variant frontotemporal dementia.

Aim

To learn more about the safety of LMTM over time, and to enable participants in prior clinical studies to continue on treatment with LMTM until it is evaluated for general use.

Hypothesis

Microtubular associated protein tau forms neurofibrillary tangles, a critical component of the pathology of Alzheimer's disease and frontotemporal dementia. LMTM dissolves toxic tau proteins and slows the progression of dementia.

Study Code: TRx-237-020

Ethics approval

Bellberry Ethics Committee

Funding

TauRx Therapeutics

Criteria

To be eligible for this study subjects must have participated in either the TRx-237-015 (Alzheimer's disease) or TRx-237-007 (Frontotemporal dementia) clinical trials

Duration of study

12 months

Contact

Professor Peter K Panegyres
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005
Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au